Tatva Chintan Pharma Chem · NSE: TATVA · BSE: 543321
Q2 FY22 results · Jul–Sep 2021
Tatva Chintan Pharma Chem reported revenue from operations of ₹123.61 crore and net profit of ₹32.41 crore for Q2 FY22 (Jul–Sep 2021), on a consolidated basis.
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 123.61 | — | — | 106.83 | +15.7% |
| Other income | 2.80 | — | — | 2.97 | −5.5% |
| Total income | 126.42 | — | — | 109.80 | +15.1% |
| Profit before tax | 35.42 | — | — | 24.26 | +46.0% |
| Net profit for the period | 32.41 | — | — | 23.15 | +40.0% |
| EPS, basic (₹) | 15.02 | — | — | 11.52 | not comparable |
| Net margin (%) | 26.2 | — | 21.7 |
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 116.69 | — | — | 107.65 | +8.4% |
| Other income | 2.60 | — | — | 2.77 | −6.3% |
| Total income | 119.28 | — | — | 110.42 | +8.0% |
| Profit before tax | 33.55 | — | — | 24.98 | +34.3% |
| Net profit for the period | 30.72 | — | — | 23.96 | +28.2% |
| EPS, basic (₹) | 14.24 | — | — | 11.93 | not comparable |
| Net margin (%) | 26.3 | — | 22.3 |
Consolidated
- Filed with BSE
- 25 Oct 2021, 09:51 IST
- Board meeting
- 23 Oct 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 25 Oct 2021, 09:51 IST
- Board meeting
- 23 Oct 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE